Newly Identified Gene Variants that Modify the Onset of Huntington’s Disease Could Lead to New Therapeutics

Researchers from the Mass General Research Institute have used an innovative approach to pinpoint two locations on the human genome that influence the rate at which Huntington’s disease (HD), a debilitating neurodegenerative disorder, develops in those carrying the HD gene defect.

By studying the samples from more than 4,000 HD patients, researchers were able to identify two genetic variants in areas distinct from the mutated gene that causes the disease.

These variants were more common in HD patients who developed symptoms at atypical times—either earlier or later than expected.

The findings imply that these genetic differences can alter the timing of the onset of the disease, which in turn could help devise ways to start treatment or preventative measures before symptoms appear.

James Gusella, PhD, of the Center for Genomic Medicine at Mass General, is corresponding author of the report.

LEARN MORE

About the Mass General Research Institute
Massachusetts General Hospital is home to the largest hospital-based research program in the United States. Research at Mass General takes place in over 30 departments, centers and institutes and is supported by federal and state funding, foundations, industry partners and philanthropic donations. Support our research.

Tags: , , , , , , , ,

Grateful Patient Funds New Research into Rare But Deadly Aortic Dissection

MGH Diabetes Quest Takes A Big Step

Let us know what you think!

%d bloggers like this: